Apogee Therapeutics Inc. (APGE)
(Delayed Data from NSDQ)
$38.33 USD
+1.09 (2.93%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $38.28 -0.05 (-0.13%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth C Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Apogee Therapeutics Inc.'s return on equity, or ROE, is -28.35% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.42%. While this shows that APGE has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
APGE 38.33 +1.09(2.93%)
Will APGE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for APGE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APGE
Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High?
Wall Street Analysts Think Apogee Therapeutics Inc. (APGE) Could Surge 132.72%: Read This Before Placing a Bet
APGE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 134%: Here's is How to Trade
Other News for APGE
BTIG Increases Price Target for Apogee Therapeutics (APGE) to $115 | APGE Stock News
Apogee Therapeutics price target raised by $15 at BTIG, here's why
Gold Falls 1%; ProKidney Shares Spike Higher
Apogee Therapeutics: Funding Supports Best-In-Class Ambitions In Atopic Dermatitis
12 Health Care Stocks Moving In Monday's Intraday Session